17 results about "Sustained delivery" patented technology

This disclosure relates to a drug delivery system comprising an intraocular pressure lowering agent, a neurotrophic agent, such as a CNTF compound, a C-type Natriuretic Peptide (CNP) compound, a Tie-2 agonist, a Natriuretic Peptide Receptor-B (NPR-B) compound, or an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, including any combination of these compounds and a sustained delivery component. Methods of treating a glaucoma or related conditions, medicaments, kits, uses and methods of manufacturing are also described.

Disclosed are formulations for providing an active agent. Formulations include a carrier including an active agent and mineral coated microparticles wherein an active agent is adsorbed to the mineral. Other formulations include a carrier including mineral coated microparticles wherein mineral coated microparticles include an active agent. Also disclosed are methods for sustained delivery of an active agent and methods for treating inflammatory diseases using a formulation for providing sustained delivery of an active agent.

A linker for linking a therapeutic agent to another moiety, such as the Fc region of an antibody. A linker having two or more maleimide functional groups capable of undergoing a nucleophilic conjugate addition reaction. A method for increasing the duration of action of a therapeutic agent by conjugating it to a novel linker and the Fc region of an antibody. An antibody-drug conjugate having an increased duration of action over the drug alone.

This invention relates to a silica hydrogel composite comprising inactive silica particles and solid particles of one or more active pharmaceutical ingredients. This silica hydrogel composite enables controlled and sustained delivery of the active pharmaceutical ingredient.

The invention provides a magnetic soft robot, a preparation method, a control method, a medicine loading method and application. According to the magnetic soft robot, dynamic non-Newtonian hydrogel serves as a main body material, a reversible dynamic cross-linked network is built in the magnetic soft robot, magnetic particles are compounded, a flexible soft structure with the magnetic response capacity is formed, the magnetic soft robot can be remotely driven under the action of an external magnetic field, and the magnetic soft robot is suitable for controllable movement in a limited space. The magnetic soft robot has good biocompatibility and biological safety, and can be used as a drug loading and delivery carrier for preparing a drug preparation; meanwhile, the compound shows good structural stability in a complex physiological environment, and can keep the form and function completeness under various physiological disturbance conditions, thereby supporting continuous delivery of drugs. Finally, the magnetic soft robot provides possibility for medicine preparation and delivery related applications, and is simple in structure, controllable in cost and suitable for popularization and application.

Sustained release biologics can be prepared by emulsifying a Solid-in-Hydrocarbon (S / H) mixture in a fluorocarbon solution to form an emulsion of the S / H in the fluorocarbon solution. Advantageously, the Solid-in-Hydrocarbon (S / H) mixture can be prepared by dispersing spray dried biologic particles in a solution of a sustained release polymer in a hydrocarbon solvent. Further, the spray dried biologic particles can be prepared by atomizing a feed solution including a biologic drug in an aqueous carrier to form an aerosol and exposing the aerosol to a stream of drying gas at a temperature of greater than about 80 °C, e.g., from about 80 °C to about 150 °C, to dry the aerosol to form the spray dried biologic particles. In some aspects, emulsifying the S / H mixture in the fluorocarbon solution can be carried out with a microporous membrane.

This invention provides a sustained delivery hydrogel comprising a crosslinked minoxidil-aldehyde-modified polymer for treatment of hair loss. Also provided herein is a sustained delivery hydrogel comprising a crosslinked minoxidil-aldehyde-modified hyaluronic acid derivative for treatment of hair loss. The invention also relates to methods for inducing anagen phase of hair growth, prolonging the anagen phase, increasing hair follicle size, reversing, preventing or inhibiting miniaturization of the hair follicle, and combinations thereof in a subject having hair loss, comprising administering the sustained delivery hydrogel comprising the crosslinked minoxidil-aldehyde-modified hyaluronic acid derivative to an area of hair loss of the subject, and to methods for inducing anagen phase of hair growth, prolonging the anagen phase, increasing hair follicle size, reversing, preventing or inhibiting miniaturization of the hair follicle, and combinations thereof in a subject having hair loss, comprising administering the sustained delivery hydrogel comprising the crosslinked minoxidil-aldehyde-modified polymer to an area of hair loss of the subject.

Provided here within is a saliva-activated pharmaceutical composition for use in an intra-oral sustained-release sachet. The formulation includes acacia powder in defined acacia-to-levodopa ratios effective to increase levodopa solubility by at least 300% at 25° C., maintain a localized pH of 3-5, and suppress levodopa oxidation during and after intra-oral use. In combination with levodopa, carbidopa, ascorbic acid, and optional palatability or swallowing-stimulation agents, the acacia forms a hydrocolloid matrix that stabilizes drug particles, enhances dispersion, and enables sustained, uniform release for several hours. The composition further supports consistent distribution of flavoring agents and prolonged intra-oral retention with improved sensory persistence. This acacia-dependent hydrocolloid system provides controlled salivary dissolution, biochemical stabilization, and predictable sustained delivery of levodopa / carbidopa, achieving performance not obtained with prior acacia-based formulations or with the parent sachet device.

This disclosure relates to a drug delivery system comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (FAS) or FAS-ligand (FASL) inhibitor, a tumor necrosis factor-α (TNF-α) or TNF receptor (TNFR) inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease (caspase) inhibitor, including any combination of these compounds and, optionally, a sustained delivery component. This type of drug delivery system can be used to treat a medical condition such as an inherited or age-related choroid, retina, optic nerve disorder, or optic nerve degeneration; an otic disorder; a neurologic or CNS disorder; or a related condition; or a condition related to occlusion or obstruction of a blood vessel or blood circulation such as a stroke, myocardial or renal infarction. Medicaments, methods of manufacturing medicaments, kits, and other related products or methods are also described.

Hollow hydroxyapatite microparticles are provided for sustained delivery of an agent that provides osteoprotegerin anti-osteolytic activity for treatment of post-orthodontic relapse and bone disorders. In particular, methods of using such microparticles for post-orthodontic tooth stabilization and bone regeneration and repair are provided.

Pegylated lipids are combined with cationic amine-containing polymers and copolymers and amphipathic compounds to form stabilized transfection complexes for sustained delivery of nucleic acids to cells in biological systems, specifically for in vitro cell transfection research.

According to the present disclosure, the use of a nanoliposome in the manufacture of a medicament for the prophylaxis and / or treatment of anterior segment ocular diseases is provided. The nanoliposome comprises a plurality of unsaturated and / or saturated lipids forming at least one lipid bilayer encapsulating a hydrophobic drug comprising tacrolimus, wherein the hydrophobic drug and the plurality of unsaturated and / or saturated lipids have a weight ratio of up to 0.2. The present disclosure also provides for such a nanoliposome and a method of preventing and / or treating anterior segment ocular diseases based on the nanoliposomes.

The utility model relates to the technical field of fastener cleaning, in particular to a fastener cleaning and drying device which comprises a cleaning box, the bottom of the cleaning box is fixedly connected with a water delivery pump, the output end of the water delivery pump is communicated with a water delivery pipe, and the output end of the water delivery pipe is communicated with the interior of the top of the cleaning box. The top of the other end of the cleaning box is fixedly connected with an output plate, and a cleaning assembly used for evenly cleaning the fasteners is arranged in the cleaning box. Through the arrangement of the cleaning assembly and the cooperation of the first conveying belt and the rotating cylinder, continuous conveying and multi-angle overturning cleaning of the fasteners are effectively achieved; by means of the structure, the traditional cleaning limitation that only pushing is conducted without turning over can be broken through, multi-angle turning over and brushing of fasteners in the conveying and rotating process are achieved, the cleaning uniformity and thoroughness are remarkably improved, and the high-standard cleaning requirement is met.

Formulations for delivering active agents are disclosed. The formulations include a carrier comprising an active agent and mineral-coated microparticles, wherein the active agent is adsorbed onto the mineral. Other formulations include a carrier comprising mineral-coated microparticles, wherein the mineral-coated microparticles contain the active agent. Methods for sustained delivery of active agents and methods for treating inflammatory diseases using formulations providing sustained delivery of active agents are also disclosed.

A therapeutic sustained delivery vehicle (TSDV) includes a plurality of microparticles with pirfenidone (PFD) within a poly(lactic-co-glycolic acid) (PLGA) matrix, where the microparticles are suspended in a hyaluronic acid (HA) solution. This suspension of microparticles are useful for injection into a joint that suffers from osteoarthritis (OA) inflammation and pain. The microparticles are microspheres formed by forming a solution of PDF and PLGA in a water insoluble organic solvent that is emulsified with an aqueous solution. Upon evaporation of the organic solvent the resulting microspheres are separated from the suspension. The microspheres are suspended in a HA solution. An OA treatment is a periodic injection protocol that provides a long-term in vivo controlled-release PFD to modulate and attenuate the OA progression.

An implant is disclosed for the sustained delivery of a drug. The implant comprises a core comprising at least one drug distributed uniformly in a polymer matrix of a first non-erodible polymer. The i